ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,533,422, issued on Jan. 27, was assigned to CureVac SE (Tubingen, Germany).
"Modified RNA with decreased immunostimulatory properties" was invented by Thomas Schlake (Gundelfingen, Germany) and Andreas Thess (Kusterdingen, Germany).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a method for providing modified mRNAs of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy."
The patent was filed on Dec. 29, 2020...